---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-002696"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:32:35.274885+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa outlines 2024 milestones: Fast Track for MRT-2359, MRT-6160 Phase 1, cash into H1 2026

## Summary
- FDA Fast Track Designation for MRT-2359 in previously treated metastatic SCLC with L-MYC or N-MYC expression.
- RP2D for MRT-2359 Phase 1/2 trial in MYC-driven solid tumors expected Q2 2024; new dose schedule initiated.
- MRT-6160 (VAV1-directed MGD) IND submission H1 2024, Phase 1 SAD/MAD study in healthy volunteers mid-2024.
- Cash runway into H1 2026; NEK7 development candidate nomination Q1 2024, CDK2 candidate in 2024.

## SEC filing metadata
- accession: 0000950170-24-002696
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000095017024002696/0000950170-24-002696-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000095017024002696/glue-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-002696
- JSON: https://secwatch.observer/filing/0000950170-24-002696.json
- Plain text: https://secwatch.observer/filing/0000950170-24-002696.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.